Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2
- Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 | Sarepta Therapeutics, Inc. Investor Relations | Sarepta Therapeutics, Inc.
- Sarepta’s next DMD drug seems to get the job done, but Elevidys casts long shadow FierceBiotech
- Sarepta’s new Duchenne drug outperforms bestseller Exondys in trial Reuters
- Sarepta Therapeutics (SRPT) Announces Positive Data from Part B of MOMENTUM Study StreetInsider.com
- Sarepta says its experimental Duchenne drug more effective than older medicine XM
Read More: Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2